A Study of NanoPac in Non Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 14 May 2019 According to a NanOlogy media release, the company is finalizing preclinical work of inhaled NanoPac in preparation for an investigational new drug (IND) submission to the US FDA in mid-2019 to allow for this clinical trial in NSCLC.
- 26 Sep 2018 New trial record
- 18 Sep 2018 According to a DFB Soria media release, this trial is planned for 2019.